Shamini Jain1, Paul J Mills. 1. UCLA Division of Cancer Prevention and Control Research, Los Angeles, CA, USA. sjain@ucsd.edu
Abstract
BACKGROUND: Biofield therapies (such as Reiki, therapeutic touch, and healing touch) are complementary medicine modalities that remain controversial and are utilized by a significant number of patients, with little information regarding their efficacy. PURPOSE: This systematic review examines 66 clinical studies with a variety of biofield therapies in different patient populations. METHOD: We conducted a quality assessment as well as a best evidence synthesis approach to examine evidence for biofield therapies in relevant outcomes for different clinical populations. RESULTS: Studies overall are of medium quality, and generally meet minimum standards for validity of inferences. Biofield therapies show strong evidence for reducing pain intensity in pain populations, and moderate evidence for reducing pain intensity hospitalized and cancer populations. There is moderate evidence for decreasing negative behavioral symptoms in dementia and moderate evidence for decreasing anxiety for hospitalized populations. There is equivocal evidence for biofield therapies' effects on fatigue and quality of life for cancer patients, as well as for comprehensive pain outcomes and affect in pain patients, and for decreasing anxiety in cardiovascular patients. CONCLUSION: There is a need for further high-quality studies in this area. Implications and future research directions are discussed.
BACKGROUND: Biofield therapies (such as Reiki, therapeutic touch, and healing touch) are complementary medicine modalities that remain controversial and are utilized by a significant number of patients, with little information regarding their efficacy. PURPOSE: This systematic review examines 66 clinical studies with a variety of biofield therapies in different patient populations. METHOD: We conducted a quality assessment as well as a best evidence synthesis approach to examine evidence for biofield therapies in relevant outcomes for different clinical populations. RESULTS: Studies overall are of medium quality, and generally meet minimum standards for validity of inferences. Biofield therapies show strong evidence for reducing pain intensity in pain populations, and moderate evidence for reducing pain intensity hospitalized and cancer populations. There is moderate evidence for decreasing negative behavioral symptoms in dementia and moderate evidence for decreasing anxiety for hospitalized populations. There is equivocal evidence for biofield therapies' effects on fatigue and quality of life for cancerpatients, as well as for comprehensive pain outcomes and affect in painpatients, and for decreasing anxiety in cardiovascularpatients. CONCLUSION: There is a need for further high-quality studies in this area. Implications and future research directions are discussed.
Authors: Cecile A Lengacher; Mary P Bennett; Kevin E Kip; Rosemary Keller; Melisa S LaVance; Lynette S Smith; Charles E Cox Journal: Oncol Nurs Forum Date: 2002 Nov-Dec Impact factor: 2.172
Authors: Gudrun Pohl; Heidemarie Seemann; Niklas Zojer; Christina Ochsner; Christine Luhan; Michael Schemper; Heinz Ludwig Journal: Support Care Cancer Date: 2006-10-13 Impact factor: 3.603
Authors: Dawn S Wilkinson; Pamela L Knox; James E Chatman; Terrance L Johnson; Nilufer Barbour; Yvonne Myles; Antonio Reel Journal: J Altern Complement Med Date: 2002-02 Impact factor: 2.579
Authors: Susan K Lutgendorf; Elizabeth Mullen-Houser; Daniel Russell; Koen Degeest; Geraldine Jacobson; Laura Hart; David Bender; Barrie Anderson; Thomas E Buekers; Michael J Goodheart; Michael H Antoni; Anil K Sood; David M Lubaroff Journal: Brain Behav Immun Date: 2010-06-30 Impact factor: 7.217
Authors: Mohammad Reza Nourbakhsh; Thomas J Bell; Jason Benson Martin; Amir Massoud Arab Journal: J Altern Complement Med Date: 2016-08-03 Impact factor: 2.579
Authors: Becky Kinkead; Pamela J Schettler; Erika R Larson; Dedric Carroll; Margaret Sharenko; James Nettles; Sherry A Edwards; Andrew H Miller; Mylin A Torres; Boadie W Dunlop; Jeffrey J Rakofsky; Mark Hyman Rapaport Journal: Cancer Date: 2017-10-17 Impact factor: 6.860